

## HR 1587

### Preservation of Antibiotics for Medical Treatment Act of 2017

**Congress:** 115 (2017–2019, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 16, 2017

**Current Status:** ASSUMING FIRST SPONSORSHIP - Ms. DeLauro asked unanimous consent that she may hereafter be considered

**Latest Action:** ASSUMING FIRST SPONSORSHIP - Ms. DeLauro asked unanimous consent that she may hereafter be considered as the first sponsor of H.R. 1587 a bill originally introduced by former Representative Slaughter, for purposes of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection. (May 8, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/house-bill/1587>

#### Sponsor

**Name:** Rep. Slaughter, Louise McIntosh [D-NY-25]

**Party:** Democratic • **State:** NY • **Chamber:** House

## Cosponsors (50 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Mar 16, 2017
Rep. Cicilline, David N. [D-RI-1]	D · RI		Mar 16, 2017
Rep. Connolly, Gerald E. [D-VA-11]	D · VA		Mar 16, 2017
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Mar 16, 2017
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Mar 16, 2017
Rep. Deutch, Theodore E. [D-FL-22]	D · FL		Mar 16, 2017
Rep. Jeffries, Hakeem S. [D-NY-8]	D · NY		Mar 16, 2017
Rep. Langevin, James R. [D-RI-2]	D · RI		Mar 16, 2017
Rep. Lieu, Ted [D-CA-33]	D · CA		Mar 16, 2017
Rep. Lowenthal, Alan S. [D-CA-47]	D · CA		Mar 16, 2017
Rep. McCollum, Betty [D-MN-4]	D · MN		Mar 16, 2017
Rep. Moulton, Seth [D-MA-6]	D · MA		Mar 16, 2017
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Mar 16, 2017
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		Mar 16, 2017
Rep. Speier, Jackie [D-CA-14]	D · CA		Mar 16, 2017
Rep. Tsongas, Niki [D-MA-3]	D · MA		Mar 16, 2017
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Mar 16, 2017
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 5, 2017
Rep. Ellison, Keith [D-MN-5]	D · MN		Apr 5, 2017
Rep. Lee, Barbara [D-CA-13]	D · CA		Apr 5, 2017
Rep. Moore, Gwen [D-WI-4]	D · WI		Apr 5, 2017
Rep. Pingree, Chellie [D-ME-1]	D · ME		Apr 5, 2017
Rep. Schiff, Adam B. [D-CA-28]	D · CA		Apr 5, 2017
Rep. Takano, Mark [D-CA-41]	D · CA		Apr 5, 2017
Rep. Huffman, Jared [D-CA-2]	D · CA		May 23, 2017
Rep. Lofgren, Zoe [D-CA-19]	D · CA		May 23, 2017
Rep. Gabbard, Tulsi [D-HI-2]	D · HI		Jun 12, 2017
Rep. Aguilar, Pete [D-CA-31]	D · CA		Jul 12, 2017
Rep. Levin, Sander M. [D-MI-9]	D · MI		Jul 12, 2017
Rep. Evans, Dwight [D-PA-2]	D · PA		Oct 2, 2017
Rep. Larsen, Rick [D-WA-2]	D · WA		Oct 2, 2017
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Oct 4, 2017
Rep. McGovern, James P. [D-MA-2]	D · MA		Oct 4, 2017
Rep. Polis, Jared [D-CO-2]	D · CO		Oct 4, 2017
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Oct 4, 2017
Rep. Tonko, Paul [D-NY-20]	D · NY		Oct 4, 2017
Rep. Cohen, Steve [D-TN-9]	D · TN		Oct 6, 2017
Rep. Meng, Grace [D-NY-6]	D · NY		Oct 6, 2017
Rep. Price, David E. [D-NC-4]	D · NC		Oct 6, 2017
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Oct 6, 2017
Rep. Smith, Adam [D-WA-9]	D · WA		Oct 6, 2017

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Oct 6, 2017
Rep. Gutierrez, Luis V. [D-IL-4]	D · IL		Oct 19, 2017
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Oct 19, 2017
Rep. Roybal-Allard, Lucille [D-CA-40]	D · CA		Oct 19, 2017
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Dec 6, 2017
Rep. Lipinski, Daniel [D-IL-3]	D · IL		Dec 19, 2017
Rep. Demings, Val Butler [D-FL-10]	D · FL		May 23, 2018
Rep. Chu, Judy [D-CA-27]	D · CA		Jun 20, 2018
Rep. Larson, John B. [D-CT-1]	D · CT		Oct 2, 2018

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 17, 2017

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Mar 16, 2017)

### Preservation of Antibiotics for Medical Treatment Act of 2017

This bill amends the Federal Food, Drug, and Cosmetic Act to require an applicant for approval of a new animal drug that is a medically important antimicrobial to demonstrate that there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to the nontherapeutic use of the drug.

Medically important antimicrobials are drugs intended for use in food-producing animals that contain: (1) specified antibiotics, or (2) certain drugs on the World Health Organization's list of critically important antimicrobials.

Two years after enactment of this bill, the Food and Drug Administration (FDA) must withdraw approval of a drug's nontherapeutic use in food-producing animals unless the FDA makes a determination that, based on the application holder's demonstration or an FDA risk analysis, there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use.

The FDA must rescind an exemption for investigational use of, or approval of a new drug application for, a medically important antimicrobial for its nontherapeutic use in food-producing animals two years after the exemption is granted or the application for approval is submitted unless there is a reasonable certainty of no harm to human health from antimicrobial resistance attributable to nontherapeutic use.

A medically important antimicrobial cannot be administered (including through animal feed) to a food-producing animal for disease control unless there is a significant risk that a disease or infection present on the premises will be transmitted to the animal.

## Actions Timeline

---

- **May 8, 2018:** ASSUMING FIRST SPONSORSHIP - Ms. DeLauro asked unanimous consent that she may hereafter be considered as the first sponsor of H.R. 1587 a bill originally introduced by former Representative Slaughter, for purposes of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection.
- **Mar 17, 2017:** Referred to the Subcommittee on Health.
- **Mar 16, 2017:** Introduced in House
- **Mar 16, 2017:** Referred to the House Committee on Energy and Commerce.